CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 5 enrolled
Drug / intervention
Zolpidem Tartrate +1 moredrug
Likely dose
Zolpidem Tartrate 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03307005
NCT03307005Phase 4Completed
CompareCT.gov

Improving Sleep Quality in Heart Failure

Johns Hopkins University·interventional·Posted Oct 11, 2017·Updated Feb 11, 2020

In Brief

A Phase 4 clinical trial evaluating Zolpidem Tartrate and Placebo oral capsule for Sleep Disturbance and Heart Failure. Completed, enrolled 5 participants across 1 site.

Detailed Summary

Poor sleep quality is common in patients with heart failure. The limited available evidence intimates that improving sleep quality in patients with heart failure may improve morbidity and quality of life in this patient population. However, there is a paucity of evidence assessing the use of effective pharmacologic therapies in heart failure. The nonbenzodiazepine, GABA receptor agonist, zolpidem, has been found to have considerable benefits over traditional benzodiazepines as a soporific medication. The investigators hypothesize that zolpidem will safely improve sleep quality in patients with heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep Disturbance, Heart Failure
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 11, 2017
Enrollment StartNov 1, 2017
Primary CompletionJan 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.7 years ago

Interventions

Zolpidem Tartratedrug

Zolpidem tartrate 5 mg capsule one per night taken for 7 nights

Placebo oral capsuledrug

Placebo capsule one per night taken for 7 nights